Pegloticase injection
Products billed under this code include Krystexxa.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Krystexxa.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Krystexxa | Amgen Inc | 75987-0058-01 | 8 | $32,005.032 |
| Krystexxa | Amgen Inc | 75987-0080-10 | 8 | $32,005.032 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $4,000.629 | +$71.292 | 1 MG | Pegloticase injection | v1, posted September 17, 2026 |
| 3Q26 | $3,929.337 | +$104.814 | 1 MG | Pegloticase injection | v1, posted September 15, 2026 |
| 2Q26 | $3,824.523 | +$55.714 | 1 MG | Pegloticase injection | v1, posted September 15, 2026 |
| 1Q26 | $3,768.809 | +$107.975 | 1 MG | Pegloticase injection | v1, posted September 15, 2026 |
| 4Q25 | $3,660.834 | +$21.971 | 1 MG | Pegloticase injection | v1, posted September 8, 2026 |
| 3Q25 | $3,638.863 | +$73.545 | 1 MG | Pegloticase injection | v1, posted March 10, 2026 |
| 2Q25 | $3,565.318 | +$15.27 | 1 MG | Pegloticase injection | v1, posted March 10, 2026 |
| 1Q25 | $3,550.048 | +$67.894 | 1 MG | Pegloticase injection | v1, posted December 19, 2025 |
| 4Q24 | $3,482.154 | +$35.097 | 1 MG | Pegloticase injection | v1, posted June 11, 2025 |
| 3Q24 | $3,447.057 | +$55.143 | 1 MG | Pegloticase injection | v1, posted June 11, 2025 |
| 2Q24 | $3,391.914 | +$20.838 | 1 MG | Pegloticase injection | v1, posted March 11, 2025 |
| 1Q24 | $3,371.076 | +$64.031 | 1 MG | Pegloticase injection | v1, posted December 19, 2024 |
| 4Q23 | $3,307.045 | +$38.595 | 1 MG | Pegloticase injection | v1, posted October 10, 2024 |
| 3Q23 | $3,268.45 | +$66.589 | 1 MG | Pegloticase injection | v1, posted June 5, 2024 |
| 2Q23 | $3,201.861 | +$6.881 | 1 MG | Pegloticase injection | v1, posted February 23, 2024 |
| 1Q23 | $3,194.98 | +$51.476 | 1 MG | Pegloticase injection | v1, posted December 6, 2023 |
| 4Q22 | $3,143.504 | +$32.946 | 1 MG | Pegloticase injection | v1, posted June 22, 2023 |
| 3Q22 | $3,110.558 | +$124.712 | 1 MG | Pegloticase injection | v1, posted June 9, 2023 |
| 2Q22 | $2,985.846 | +$17.241 | 1 MG | Pegloticase injection | v1, posted December 14, 2022 |
| 1Q22 | $2,968.605 | +$7.695 | 1 MG | Pegloticase injection | v1, posted June 8, 2022 |
| 4Q21 | $2,960.91 | +$60.495 | 1 MG | Pegloticase injection | v1, posted June 2, 2022 |
| 3Q21 | $2,900.415 | +$100.751 | 1 MG | Pegloticase injection | v1, posted June 2, 2022 |
| 2Q21 | $2,799.664 | +$28.375 | 1 MG | Pegloticase injection | v1, posted March 1, 2022 |
| 1Q21 | $2,771.289 | – | 1 MG | Pegloticase injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.